You are here

  • Home
  • Archive
  • Volume 12, Issue 11
  • INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection …

Article info

Article menu

Download PDFPDF

Pharmacology and therapeutics
Protocol
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial

Authors

  • Anushka Naidoo Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa PubMed articlesGoogle scholar articles
  • Kelly E Dooley Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Kogieleum Naidoo Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South AfricaMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa PubMed articlesGoogle scholar articles
  • Nesri Padayatchi Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South AfricaMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa PubMed articlesGoogle scholar articles
  • Nonhlanhla Yende-Zuma Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa PubMed articlesGoogle scholar articles
  • Rubeshan Perumal Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South AfricaMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa PubMed articlesGoogle scholar articles
  • Gillian Dorse Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa PubMed articlesGoogle scholar articles
  • Resha Boodhram Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa PubMed articlesGoogle scholar articles
  • Emmanuella Chinonso Osuala Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Anushka Naidoo; anushka.naidoo{at}caprisa.org
View Full Text

Citation

Naidoo A, Dooley KE, Naidoo K, et al
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial
BMJ Open 2022;12:e067765. doi: 10.1136/bmjopen-2022-067765

Publication history

  • Received August 25, 2022
  • Accepted October 14, 2022
  • First published November 10, 2022.
Online issue publication 
December 29, 2023
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.